These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37326291)

  • 1. Dupilumab as a novel therapy for epidermolysis bullosa pruriginosa.
    Shao L; Zhong DQ; Liu YM; Wang JQ
    Int J Dermatol; 2023 Oct; 62(10):e542-e545. PubMed ID: 37326291
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab.
    Caroppo F; Milan E; Giulioni E; Belloni Fortina A
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e365-e367. PubMed ID: 34927769
    [No Abstract]   [Full Text] [Related]  

  • 3. Amelioration of dystrophic epidermolysis bullosa pruriginosa symptoms with dupilumab: A case report.
    Wang Y; Zhou M; Zhang L; Zheng S; Hong Y; Gao XH
    Dermatol Ther; 2021 Nov; 34(6):e15130. PubMed ID: 34528352
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.
    Shehadeh W; Sarig O; Bar J; Sprecher E; Samuelov L
    Br J Dermatol; 2020 Jun; 182(6):1495-1497. PubMed ID: 31899820
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab.
    Roque Quintana B; Piqué Durán E; Pérez Cejudo JA
    Actas Dermosifiliogr; 2024 Feb; 115(2):184-186. PubMed ID: 36871818
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to 'A case of dystrophic epidermolysis bullosa pruriginosa treated with dupilumab' by Caroppo et al.
    Martora F; Fabbrocini G; Nappa P; Marasca C; Patruno C; Scalvenzi M; Napolitano M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e729-e730. PubMed ID: 35604042
    [No Abstract]   [Full Text] [Related]  

  • 7. Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab.
    Yang DY; Jing WW; Liu X; Li L; Lu T; Li XL
    Adv Skin Wound Care; 2024 Feb; 37(2):1-4. PubMed ID: 38241457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermolysis bullosa pruriginosa treated with dupilumab.
    Zhou AG; Little AJ; Antaya RJ
    Pediatr Dermatol; 2021 Mar; 38(2):526-527. PubMed ID: 33336814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of epidermolysis bullosa pruriginosa by dupilumab.
    Wu XG; Yan S; Jiang JQ; Zhou TT; Fang X; Yang H; Bai XM; Wang H; Luo X
    J Dermatol; 2023 Jun; 50(6):837-842. PubMed ID: 36694424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.
    Yu L; Wang J; Bian L; Li Z; Li M; Li J; Zhang S
    Dermatitis; 2023; 34(1):58-59. PubMed ID: 36705654
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful use of cyclosporine in epidermolysis bullosa pruriginosa.
    Kaushik A; Mahajan R; Karim A; Handa S; De D; Saikia B
    Dermatol Ther; 2020 Nov; 33(6):e14489. PubMed ID: 33131200
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab in the treatment of dystrophic epidermolysis bullosa: off-label use in a pediatric patient.
    Xará J; Relvas M; Figueiredo C; Calvão J; Batista M; Ramos L
    Int J Dermatol; 2023 Dec; 62(12):e617-e618. PubMed ID: 37622659
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of a novel COL7A1 variant associated with dystrophic epidermolysis bullosa pruriginosa responding effectively to dupilumab.
    Zhao C; Cao S; Gao X; Xu X; Gu L
    Mol Genet Genomic Med; 2023 Nov; 11(11):e2258. PubMed ID: 37676173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermolysis bullosa pruriginosa with extensive truncal involvement treated with upadacitinib.
    Kim N; Jue MS; Huh YJ; Sung KJ; Kim H; Kim JE; Ko JY
    J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e215-e217. PubMed ID: 35964304
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermolysis Bullosa Pruriginosa Treated With Baricitinib.
    Jiang X; Wang H; Lee M; Lin Z
    JAMA Dermatol; 2021 Oct; 157(10):1243-1244. PubMed ID: 34468689
    [No Abstract]   [Full Text] [Related]  

  • 16. Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment.
    Pallesen KAU; Lindahl KH; Bygum A
    Acta Derm Venereol; 2019 Nov; 99(12):1195-1196. PubMed ID: 31453628
    [No Abstract]   [Full Text] [Related]  

  • 17. Bullous dermolysis of the newborn and dystrophic epidermolysis bullosa pruriginosa within the same family: two phenotypes associated with a COL7A1 mutation.
    Murase K; Kanoh H; Ishii N; Hashimoto T; Nakano H; Sawamura D; Seishima M
    Acta Derm Venereol; 2011 Oct; 91(6):730-1. PubMed ID: 21629976
    [No Abstract]   [Full Text] [Related]  

  • 18. Cemiplimab treatment of squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa.
    Vasilev P; Kalev D; Karamanliev M; Dimitrov D; Troyanova P; Yordanova I
    J Dtsch Dermatol Ges; 2023 Mar; 21(3):295-297. PubMed ID: 36855845
    [No Abstract]   [Full Text] [Related]  

  • 19. An incompletely penetrant novel mutation in COL7A1 causes epidermolysis bullosa pruriginosa and dominant dystrophic epidermolysis bullosa phenotypes in an extended kindred.
    Yang CS; Lu Y; Farhi A; Nelson-Williams C; Kashgarian M; Glusac EJ; Lifton RP; Antaya RJ; Choate KA
    Pediatr Dermatol; 2012; 29(6):725-31. PubMed ID: 22515571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four novel and two recurrent glycine substitution mutations in the COL7A1 gene in Chinese patients with epidermolysis bullosa pruriginosa.
    Tang ZL; Lin ZM; Wang HJ; Chen Q; Xu XM; Ge HF; Yang Y
    Clin Exp Dermatol; 2013 Mar; 38(2):197-9. PubMed ID: 23397949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.